

Supplemental Information for

## Abnormal RasGRP1 expression in the post-mortem brain and blood serum of schizophrenia patients.

Arianna De Rosa<sup>1,#</sup>, Anna Di Maio<sup>1,#</sup>, Silvia Torretta<sup>2</sup>, Martina Garofalo<sup>1,3</sup>, Valentina Giorgelli<sup>2</sup>, Rita Masellis<sup>2</sup>, Tommaso Nuzzo<sup>1,3</sup>, Francesco Errico<sup>1,5</sup>, Alessandro Bertolino<sup>2,5</sup>, Srinivasa Subramaniam<sup>6</sup>, Antonio Rampino<sup>2,5,\*</sup> and Alessandro Usiello<sup>1,3,\*</sup>

<sup>1</sup> Laboratory of Translational Neuroscience, CEINGE Biotecnologie Avanzate, 80145, Naples, Italy, [derosaar@ceinge.unina.it](mailto:derosaar@ceinge.unina.it) (A.D.R.); [dimaio@ceinge.unina.it](mailto:dimaio@ceinge.unina.it) (A.D.M.); [garofalom@ceinge.unina.it](mailto:garofalom@ceinge.unina.it) (M.G.); [nuzzo@ceinge.unina.it](mailto:nuzzo@ceinge.unina.it) (T.N.); [erricof@ceinge.unina.it](mailto:erricof@ceinge.unina.it) (F.E.)

<sup>2</sup> Group of Psychiatric Neuroscience, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, 70124, Bari, Italy, [silvia.torretta@uniba.it](mailto:silvia.torretta@uniba.it) (S.T.), [valegio3@gmail.com](mailto:valegio3@gmail.com) (V.G.); [rita.masellis@uniba.it](mailto:rita.masellis@uniba.it) (R.M.); [antonio.rampino@uniba.it](mailto:antonio.rampino@uniba.it) (A.R.)

<sup>3</sup> Department of Environmental, Biological and Pharmaceutical Science and Technologies, Università degli Studi della Campania "Luigi Vanvitelli", 81100, Caserta, Italy; [usiello@ceinge.unina.it](mailto:usiello@ceinge.unina.it) (A.U.)

<sup>4</sup> Department of Agricultural Sciences, University of Naples "Federico II", Naples, Italy; [francesco.errico@unina.it](mailto:francesco.errico@unina.it) (F.E.)

<sup>5</sup> Azienda Ospedaliero-Universitaria Consorziale Policlinico, 70124, Bari, Italy; [alessandro.bertolino@uniba.it](mailto:alessandro.bertolino@uniba.it) (A.B.)

<sup>6</sup> Department of Neuroscience, The Scripps Research Institute, Florida, Jupiter, Florida, 33458, USA.; [SSubrama@scripps.edu](mailto:SSubrama@scripps.edu), (S.S)

# Share the Co-First authorship

\* Correspondence: [usiello@ceinge.unina.it](mailto:usiello@ceinge.unina.it); Tel.: +39-0813737899 (A.U.); [antonio.rampino@uniba.it](mailto:antonio.rampino@uniba.it); Tel.: +39 080 5478588 (A.R.)

**Table S1.** Demographic characteristics, comorbidities, clinical diagnosis of each control subject and schizophrenia patient.

Control						Schizophrenia					
ID	Sex	Age (years)	PMI (hours)	pH	Clinical Diagnosis	ID	Sex	Age (years)	PMI (hours)	pH	Antipsychotic medication
1	M	47	12.5	6.53	CA (esophagus) with metastases to the liver	21	M	46	21.7	6.45	Schizophrenia, Depression, Bipolar, Seizure disorder, Epilepsy, Substance abuse
2	M	66	17.3	6.49	CA (lung), COPD	22	M	55	10.7	N.A.	Schizophrenia, Suicide, Overdose, Depression, Anxiety, Hypochondriasis
3	F	92	23.3	6.75	CA (uterus, stomach), Congestive heart failure, Hypertension, Macular degeneration,	23	M	53	20.5	N.A.	Schizophrenia, Depression, Bipolar, CA (lung) Paranoia, Psychosis, Hypertension, Anxiety
4	M	84	11.8	6.79	CA (stomach), Renal failure, acute, COPD	24	M	70	24.0	6.56	Schizophrenia, Paranoia, Aggressive behavior, Dementia, Impulse disorder, Tuberculosis
5	M	70	11.8	6.62	Coronary heart disease, Leukemia, Type I diabetes, Myocardial infarction, Congestive	25	M	35	35.7	6.51	Schizophrenia, Alcohol abuse
6	M	87	9.3	6.76	Congestive heart failure, Atherosclerosis, COPD	26	F	32	12.3	6.51	Schizophrenia, Alcohol abuse history
7	M	58	9.0	6.32	CA (colon)	27	M	61	28.0	6.73	Schizophrenia, Aggressive behavior, Suicide, Attempts, Anxiety, Tobacco abuse, Asthma
8	M	68	10.5	N.A.	CA (lung), Alcohol abuse, Type I diabetes, Transient Ischemic Attack	28	F	41	20.8	6.39	Schizophrenia, Suicide, Stabbing, Psychosis, Disassociated Disorders, Electroconvulsive
9	M	80	14.0	6.49	CA (bladder), Hypertension, Diabetes type II, CVA	29	F	50	13.7	N.A.	Schizophrenia, Suicide, Overdose, Aggressive behavior, Depression, Migraine, Hallucination
10	M	76	16.0	6.55	CA (lung). Pulmonary emphysema	30	M	18	26.3	6.72	Schizophrenia, Mentally retarded (clinical only), Attention Deficit Disorder, Sleep Apnea
11	M	75	11.5	6.6	CA (prostate) Coronary heart disease, Hypertension	31	M	46	11.6	6.41	Schizophrenia, Suicide, hanging, Alcohol abuse, Substance abuse (not Alcohol), Depression
12	M	66	13.3	N.A.	CA (larynx) Metastasis to bone and liver, Type I diabetes	32	F	29	27.3	6.4	Schizophrenia, Depression, Seizure Disorder, Attention Deficit Disorder, Aggressive behavior
13	M	64	17.5	6.63	Lymphoma, Coronary Artery Disease	33	M	60	10.3	N.A.	Schizophrenia, Depression, Bipolar, Alcohol abuse, Psychotic disorder, Inappropriate sexual
14	M	80	12.0	N.A.	CA (kidney) Hypertension, Atrial fibrillation, Macular degeneration, COPD	34	F	75	14.9	N.A.	Schizophrenia, CA (pancreas), Dementia, Therapeutic lobotomy, Dysphagia
15	F	83	17.6	6.41	CA (breast, uterus, colon), Macular degeneration, Chronic urinary tract infection	35	F	77	14.7	6.38	Schizophrenia, Alcohol abuse, Depression, Bipolar and Seizure disorder
16	F	79	14.0	N.A.	Coronary heart disease, Hypertension	36	M	77	26.5	6.56	Schizophrenia, Hypertension, Dementia, COPD
17	M	61	19.5	6.29	Normal	37	M	24	12.8	6.47	Schizophrenia, Depression, Substance abuse (not Alcohol), Suicide Attempts, Alcohol abuse
18	M	70	12.0	N.A.	Renal failure, acute, Diabetes type I	38	F	62	12.2	6.67	Schizophrenia, Stroke/CVA, Depression, Hypertension, Diabetes type I
19	M	72	12.2	6.54	COPD, Pulmonary emphysema	39	F	52	15.6	6.49	Schizophrenia, Depression, CA (pancreas), Diabetes Type II, Hypothyroidism, Hypertension
20	F	81	14.5	N.A.	COPD, Pneumonia, Osteoporosis, Tuberculosis	40	M	55	12.6	N.A.	Schizophrenia, Paranoid Schizophrenia, Infection Bacterial, Psychotic disorder, Hallucination

**Abbreviations:** ID: Identifier (progressive) number for each recruited subject; PMI: post-mortem interval; M: male; F: female; CA: carcinoma; COPD: chronic obstructive pulmonary disease; CVA: cerebrovascular accident; N.A.: Not Available.